ArticleFrontiers in pharmacology2025

Anticancer activity of RM-3-22: a TAZQ-based hydroxamic acid derivative targeting NSCLC in vitro and in vivo.

Essha Chatterjee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.